Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038276 | 0.80 | KEAP1 (0.48) | AKR1C3AKR1C2AKR1C1AKR1C4KEAP1 | |
| SCHEMBL30519485 | 0.79 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL30300276 | 0.79 | AKR1C2 (0.50) | AKR1C3AKR1C2AKR1C1AKR1C4KEAP1 | |
| SCHEMBL27214493 | 0.79 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL1228193 | 0.79 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL671102 | 0.79 | AKR1C2 (0.50) | AKR1C3AKR1C2AKR1C1AKR1C4KEAP1 | |
| SCHEMBL18094073 | 0.78 | NOTUM (0.41) | HSD17B10GPR35ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30673278 | 0.78 | AKR1C2 (0.64) | AKR1C3AKR1C2AKR1C1AKR1C4KEAP1 | |
| SCHEMBL30431884 | 0.78 | AKR1C3 (0.48) | AKR1C3AKR1C2AKR1C1AKR1C4KEAP1 | |
| SCHEMBL29053402 | 0.78 | KDM4E (0.47) | AKR1C2AKR1C1KEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| WO-2021016333-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2021-01-28 | — | — | WO | disclosed |
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | AKR1C3 4351/4885AKR1C2 4188/4885AKR1C1 4457/4885 |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | AKR1C3 3196/4885AKR1C2 3467/4885AKR1C1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.